Cargando…
Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor
The lack of disease-modifying treatments for Parkinson’s disease (PD) is in part due to an incomplete understanding of the disease’s etiology. Alpha-synuclein (α-syn) has become a point of focus in PD due to its connection to both familial and idiopathic cases—specifically its localization to Lewy b...
Autores principales: | Miller, Kathryn M., Mercado, Natosha M., Sortwell, Caryl E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041900/ https://www.ncbi.nlm.nih.gov/pubmed/33846345 http://dx.doi.org/10.1038/s41531-021-00179-6 |
Ejemplares similares
-
Cell therapy for Parkinson's disease: Why it doesn't work every time
por: Collier, Timothy J., et al.
Publicado: (2019) -
Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
por: Duffy, Megan F., et al.
Publicado: (2018) -
Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS
por: Miller, Kathryn M., et al.
Publicado: (2021) -
Neuroglial Senescence, α-Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson’s Disease
por: Miller, Sean J., et al.
Publicado: (2022) -
Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy
por: Sampaio, Tuane Bazanella, et al.
Publicado: (2017)